At close: January 8 at 4:00:01 PM EST
Pre-Market: 5:00:26 AM EST
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
1,171,583.00
1,159,060.00
1,136,702.00
1,105,599.00
931,032.00
Cost of Revenue
404,032.00
389,335.00
366,887.00
349,103.00
298,182.00
Gross Profit
767,551.00
769,725.00
769,815.00
756,496.00
632,850.00
Operating Expense
540,531.00
526,830.00
478,817.00
460,668.00
390,160.00
Operating Income
227,020.00
242,895.00
290,998.00
295,828.00
242,690.00
Net Non Operating Interest Income Expense
-9,660.00
-12,413.00
-7,805.00
-10,515.00
-13,479.00
Other Income Expense
-41,058.00
-44,793.00
55,466.00
16,073.00
-81,036.00
Pretax Income
176,302.00
185,689.00
338,659.00
301,386.00
148,175.00
Tax Provision
25,590.00
17,584.00
53,217.00
38,287.00
8,590.00
Net Income Common Stockholders
150,681.00
168,072.00
285,193.00
271,930.00
140,324.00
Diluted NI Available to Com Stockholders
150,681.00
168,072.00
285,193.00
271,930.00
140,324.00
Basic EPS
0.96
1.07
1.81
1.73
0.91
Diluted EPS
0.95
1.05
1.76
1.66
0.87
Basic Average Shares
157,808.25
157,708.00
157,179.00
156,876.00
154,988.00
Diluted Average Shares
160,567.75
160,774.00
161,855.00
164,116.00
161,932.00
Total Operating Income as Reported
190,811.00
206,686.00
298,944.00
296,590.00
237,296.00
Total Expenses
944,563.00
916,165.00
845,704.00
809,771.00
688,342.00
Net Income from Continuing & Discontinued Operation
150,712.00
168,105.00
285,263.00
272,051.00
140,410.00
Normalized Income
183,679.34
202,750.21
237,936.98
259,294.72
217,593.71
Interest Income
3,359.00
3,323.00
3,410.00
794.00
473.00
Interest Expense
13,019.00
15,736.00
11,215.00
11,309.00
13,952.00
Net Interest Income
-9,660.00
-12,413.00
-7,805.00
-10,515.00
-13,479.00
EBIT
189,321.00
201,425.00
349,874.00
312,695.00
162,127.00
EBITDA
300,629.00
313,136.00
457,112.00
413,764.00
249,874.00
Reconciled Cost of Revenue
404,032.00
309,334.00
291,725.00
280,526.00
238,223.00
Reconciled Depreciation
111,308.00
111,711.00
107,238.00
101,069.00
87,747.00
Net Income from Continuing Operation Net Minority Interest
150,712.00
168,105.00
285,263.00
272,051.00
140,410.00
Total Unusual Items Excluding Goodwill
-38,565.00
-38,282.00
56,140.00
14,612.00
-81,936.00
Total Unusual Items
-38,565.00
-38,282.00
56,140.00
14,612.00
-81,936.00
Normalized EBITDA
339,194.00
351,418.00
400,972.00
399,152.00
331,810.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-5,597.66
-3,636.79
8,813.98
1,855.72
-4,752.29
6/30/2021 - 2/9/1989
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INCY Incyte Corporation
73.13
-0.08%
UTHR United Therapeutics Corporation
366.61
+1.18%
ALNY Alnylam Pharmaceuticals, Inc.
240.55
+1.95%
NUVL Nuvalent, Inc.
78.25
-2.33%
BPMC Blueprint Medicines Corporation
90.63
-3.96%
PTCT PTC Therapeutics, Inc.
45.04
+0.96%
GMAB Genmab A/S
22.19
+0.05%
RPRX Royalty Pharma plc
26.20
+0.61%
ASND Ascendis Pharma A/S
134.43
-2.08%
BBIO BridgeBio Pharma, Inc.
29.45
+2.08%